The ubiquitin -proteasome system (UPS) is the principal protein degradation system that tags and targets short-lived proteins, as well as damaged or misfolded proteins, for destruction. In spinal and bulbar muscular atrophy (SBMA), the androgen receptor (AR), an Hsp90 client protein, is such a misfolded protein that tends to aggregate in neurons. Hsp90 inhibitors promote the degradation of Hsp90 client proteins via the UPS. In a transgenic mouse model of SBMA, we examined whether a functioning UPS is preserved, if it was capable of degrading polyglutamine-expanded mutant AR, and what might be the therapeutic effects of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), an oral Hsp90 inhibitor. Ubiquitin-proteasomal function was well preserved in SBMA mice and was even increased during advanced stages when the mice developed severe phenotypes. Administration of 17-DMAG markedly ameliorated motor impairments in SBMA mice without detectable toxicity and reduced amounts of monomeric and nuclear-accumulated mutant AR. Mutant AR was preferentially degraded in the presence of 17-DMAG in both SBMA cell and mouse models when compared with wild-type AR. 17-DMAG also significantly induced Hsp70 and Hsp40. Thus, 17-DMAG would exert a therapeutic effect on SBMA via preserved proteasome function.
INTRODUCTION
Polyglutamine (polyQ) diseases are inherited neurodegenerative disorders caused by the expansion of trinucleotide repeats in the causative genes (1) . One of these is spinal and bulbar muscular atrophy (SBMA), characterized by premature muscular exhaustion, progressive muscular weakness, atrophy and fasciculation in bulbar and limb muscles (2) . In SBMA, a CAG repeat with 14-32 CAGs expands to CAGs in the first exon of the androgen receptor (AR) gene (3) . Pathological findings of SBMA are lower motor neuronal loss (4) and diffuse nuclear accumulations and nuclear inclusions (NIs) of polyQ-expanded mutant AR in the residual motor neurons in the brainstem and spinal cord as well as in some other visceral organs (5) .
Heat shock protein 90 (Hsp90), a cytosolic molecular chaperone, is involved in the maturation and activation of a number of proteins, known as client proteins. Hsp90 client proteins comprise numerous oncoproteins (6) and steroid receptors, including AR (7) . Hsp90 inhibitors enhance the proteasomal degradation of † The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
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To whom correspondence should be addressed. Tel: þ81 52-744-2385; Fax: þ81 52-744-2384; Email: hadachi@med.nagoya-u.ac.jp; sobueg@med. nagoya-u.ac.jp the Hsp90 client proteins, particularly of their mutant versions (8) . Additionally, Hsp90 inhibitors also function as Hsp inducers (9) . Therefore, numerous oncoproteins belonging to the Hsp90 client protein family are selectively degraded in the ubiquitin-proteasome system (UPS) by Hsp90 inhibitors. 17-(dimethylaminoethylamino)-17-demethoxy-geldanamycin (17-DMAG; NSC707545), a potent Hsp90 inhibitor, is now under clinical trials as a novel molecular-targeted agent for a wide range of malignancies (10) . Recently, we explored the possibility of using 17-allylamino-17-demethoxygeldanamycin (17-AAG; NSC-330507), another Hsp90 inhibitor, as a therapeutic agent for SBMA and found that 17-AAG inhibits nuclear accumulation of the mutant AR protein, leading to marked amelioration of the motor phenotype of the transgenic mouse model of SBMA (AR-97Q mice) without detectable toxicity (11) . 17-DMAG is a more potent derivative of 17-AAG (12, 13) , is more water soluble than 17-AAG and can be administered orally (14) , thus possibly making it a more feasible long-term therapeutic agent for treating SBMA.
Hsp90 inhibitor-induced client protein degradation requires a well-preserved proteasome function; however, the question of whether the UPS is impaired in patients with polyQ diseases has been raised with respect to this UPS-dependent therapy (15) . It is generally considered that the UPS is involved in polyQ diseases, as many components of the UPS and molecular chaperones are known to co-localize with polyQcontaining NIs (16, 17) . Nevertheless, previous studies using proteasome assays performed in cultured cell and mouse models of polyQ diseases have not shown consistent results; the UPS was impaired in some (18) (19) (20) (21) (22) (23) (24) and preserved in others (25) (26) (27) (28) (29) . If the UPS is irreversibly damaged in patients and animal models of polyQ diseases, Hsp90 inhibitors cannot exert their pharmacological effects. Thus, it is important to assess whether the UPS is impaired, particularly in in vivo models of polyQ diseases with advanced phenotypic expressions. In this study, we employed multiple assessments to investigate whether the UPS function is preserved in transgenic AR-97Q SBMA mice and examined the effects of 17-DMAG on the phenotypic expression of SBMA in these mice.
RESULTS

Proteasomal proteolytic activity is preserved in AR-97Q mice with advanced phenotypes
To investigate proteasome functions, the chymotryptic activity of the proteasome was examined in AR-24Q (wild-type AR) and AR-97Q (mutant AR) mice at an advanced stage (16 weeks) (30) . Most 16-week-old AR-97Q mice developed the severe phenotype. Chymotryptic activities of the 26S proteasomes in the AR-97Q mice were similar to wild-type in the spinal cord (Fig. 1A , left) and increased with respect to wildtype in skeletal muscle (Fig. 1A, right) . We also examined ubiquitin-dependent proteolytic activity using 35S-labeled ubiquitinated cIAP1, a ubiquitin ligase that catalyzes its own ubiquitination for degradation. The levels of ubiquitindependent degradation in spinal cord of AR-97Q mice were not significantly different from wild-type (Fig. 1B, left) ; in skeletal muscle, however, degradation was higher in the AR-97Q mice than in the wild-type mice (Fig. 1B, right) . These assays indicate that proteasomal function in AR-97Q mice with severe phenotypes was preserved in the spinal cord and was enhanced in skeletal muscle.
Proteasomal function in Ub
G76V -GFP/AR-97Q reporter mice is preserved
The Ub G76V -GFP mouse was developed as an in vivo reporter of UPS function (31) . They express an N-terminal ubiquitin mutant (Ub G76V ) in frame with enhanced green fluorescent protein (32) . As the reporter is rapidly processed and degraded by the UPS, steady-state levels of Ub G76V -GFP are very low under wild-type conditions, but accumulate when the UPS is impaired. We evaluated levels of Ub G76V -GFP in spinal cord and skeletal muscle lysates of double transgenic, Ub G76V -GFP/AR-97Q and Ub G76V -GFP/AR-24Q mice (see Supplementary Material). Immunoblot analyses showed that Ub G76V -GFP in the AR-97Q mice was increased in the spinal cord (30%) and skeletal muscle (85%) compared with AR-24Q mice ( Fig. 2A) . These results were well correlated To assess whether the increases in reporter levels reflect UPS function or reporter mRNA expression levels, we quantified mRNA levels of Ub G76V -GFP by real-time RT -PCR and noted increases in Ub G76V -GFP mRNA levels in Ub G76V -GFP/ AR-97Q mice compared with those in Ub G76V -GFP/AR-24Q mice (Fig. 2B) . The increases in protein levels were very similar to those in mRNA levels (Fig. 2C) , strongly indicating that the increases in reporter proteins in the spinal cord and muscle were due to increased expressions of reporter protein mRNAs and that UPS function is well preserved in AR-97Q mice even in their advanced stage. Furthermore, in situ hybridization (Supplementary Material) also demonstrated an increase in Ub G76V -GFP reporter mRNA levels in the spinal motor neurons and skeletal muscle of AR-97Q mice compared with those of AR-24Q mice (Supplementary Material, Fig. S1B and D) . This increase was comparable to that seen in anti-GFP immunohistochemical staining (Supplementary Material, Fig. S1A and E), indicating again that the increased protein is due to increased reporter mRNA and that UPS function in the motor neurons of AR-97Q mice is well preserved.
Expression of proteasomal mRNAs and proteins are preserved in AR-97Q mice
To verify the protein expression levels of proteasomal subunits in advanced stage AR-24Q and AR-97Q mice, immunoblot analyses with various anti-proteasomal subunit antibodies were conducted in spinal cord and muscle lysates (Supplementary Material). The levels of all proteasome subunits, including those in the 20S proteasome (a1-7, b1-7), the 19S regulatory particles (Rpt1-6, Rpn1,2,7,8) and the proteasome activators (PA28a,b,g) in the spinal cord of AR-97Q mice, were similar to those in the AR-24Q mice ( Fig. 3A and B) . On the other hand, protein levels of all proteasomal subunits in the skeletal muscle of the AR-97Q mice were higher than those in the AR-24Q mice ( Fig. 3A and B) . Representative immunohistochemical analyses also revealed the elevated expression levels of proteasomal subunits 20S a1, a4, a5, a7, b2 and 19S Rpt3 in the skeletal muscle of AR-97Q versus AR-24Q mice (Supplementary Material, Fig. S2 ) and no differences in the patterns of proteasomal subunit stainings in the spinal anterior horn cells of the AR-24Q and AR-97Q mice (Supplementary Material, Fig. S2 ). Likewise, quantitative real-time RT-PCR analysis showed that levels of mRNA encoding representative proteasomal subunits in the spinal cords of AR-97Q mice were similar to those in AR-24Q mice (Supplementary Material, Fig. S3A ), whereas mRNA levels of the same proteasomal subunits were Fig. S3B ). Thus, the increases in proteasomal subunit mRNAs were well correlated to those in proteasomal subunit proteins, to increased chymotryptic activity and to ubiquitin-dependent degradation of 35 Slabeled cIAP1 in AR-97Q skeletal muscle. Furthermore, there was no difference in the proteasomal subunit expression levels in the spinal anterior horn cells of the AR-24Q and AR-97Q mice. Next we evaluated the co-localization of proteasomal subunits and mutant AR in AR-97Q mice. Doubleimmunofluorescence staining with anti-20S proteasome a1 or a7 subunit and mouse anti-expanded polyQ (1C2) antibodies revealed that the 20S proteasome a1 or a7 subunits (Supplementary Material, Fig. S4A To examine the efficacy of 17-DMAG to degrade mutant polyQ-expanded AR, we treated SH-SY5Y cells highly expressing either AR-24Q or AR-97Q with 17-DMAG or vehicle (DMSO). Although the anti-AR immunoblot showed a dose-dependent decline in both wild-type and mutant AR expression in response to 17-DMAG (Fig. 4A) , the decrease in monomeric mutant AR (70% at 100 nM 17-DMAG) was significantly more than in wild-type (29%; Fig. 4B ), suggesting that mutant AR is more selectively degraded by 17-DMAG than is wild-type. In addition, the pharmacological effect of 17-DMAG was three times as strong as that of 17-AAG ( Fig. 4C and D) . 17-DMAG also significantly increased the expression of both Hsp70 and Hsp40, but only slightly increased Hsp90 expression ( Fig. 4A and B ). There were no significant differences, however, in the levels of Hsp70 and Hsp40 induction in cells transfected with the wild-type or mutant AR (Fig. 4B ). There was also no difference in cell viability between wild-type-and mutant AR-transfected cells (data not shown). These data indicate that 17-DMAG preferentially degrades the mutant AR protein without cellular toxicity.
We next examined the status of the Hsp90 chaperone complex in mutant AR-expressing cultured cells treated with 17-DMAG. After 30 min of 17-DMAG treatment, immunoprecipitation with an AR-specific antibody showed that Hsp90 chaperone complex-associated Hop was markedly increased and p23 decreased in a dose-dependent manner (Fig. 4E ), suggesting that treatment with 17-DMAG shifted the ARHsp90 chaperone complex from a mature stabilizing form with p23 to a proteasome-targeting form with Hop (33). This finding is consistent with our previous report using 17-AAG (11) . Immunoprecipitation with the AR-specific antibody showed that the mutant AR was more strongly ubiquitinated in cells treated with 17-DMAG in the presence of the proteasome inhibitor MG132 than those treated with DMSO alone (Fig. 4F ). In addition, the degradation of mutant AR-97Q by 17-DMAG was completely suppressed by MG132 (Fig. 4F, bottom row) . These results suggest that following treatment with 17-DMAG, the Hsp90 chaperone complex and client proteins are targeted for degradation via the UPS as previously reported (34, 35) .
The mutant AR was shown to be degraded only when Hsp70 was induced (36) . However, mutant AR was markedly decreased following treatment with 17-DMAG, even when the induction of Hsp70 was blocked by a small interfering RNA ( Fig. 4G and H ). This suggests that 17-DMAG contributes to the preferential degradation of mutant AR through Hsp90 chaperone complex formation and subsequent proteasomedependent degradation, even without induction of Hsp70.
17-DMAG ameliorates phenotypic expression of the SBMA transgenic mouse
We administrated 17-DMAG from age 5 to 25 weeks at doses of 1.0 or 10 mg/kg to male AR-97Q or AR-24Q mice and examined various neurological and behavioral parameters. The disease progression of AR-97Q mice treated with 10 mg/kg 17-DMAG (Tg-10) was significantly ameliorated and that of mice treated with 1.0 mg/kg 17-DMAG (Tg-1) mildly ameliorated ( Fig. 5A -D) . The untreated male mice (Tg-0) showed motor impairment assessed by the Rotarod task as early as 9 weeks after birth, whereas the Tg-10 mice showed initial impairment only 16 weeks after birth and with less deterioration than the Tg-0 mice (P,0.005, Fig. 5A ). The locomotor cage activity of the Tg-0 mice was also significantly decreased at 10 weeks compared with the Tg-10 mice (P , 0.005, Fig. 5B ). The Tg-0 mice lost weight significantly earlier and more profoundly than the Tg-10 mice (P , 0.005, Fig. 5C ). 17-DMAG also significantly prolonged the survival rate of both the Tg-1 (P , 0.05) and Tg-10 (P , 0.0001) mice compared with the Tg-0 mice (Fig. 5D) . Although both the Tg-10 and Tg-1 mice showed ameliorated phenotypic expressions, the Tg-10 mice were better than the Tg-1 mice in all parameters, suggesting that the improved motor phenotype depended on drug efficacy. In addition, the Tg-0 mice showed motor weakness, taking shorter steps and dragging their legs, whereas the Tg-10 mice showed almost normal ambulation ( Fig. 5E and F) .
To evaluate the toxicity of 17-DMAG, we examined blood samples from 25-week-old mice treated with 10 mg/kg 17-DMAG for 20 weeks (Supplementary Material). Measurements of aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen and serum creatinine demonstrated that 17-DMAG resulted in neither liver nor renal dysfunction in the AR-97Q mice at the dose of 10 mg/kg (Supplementary Material, Fig. S5 ). Additionally, no treated mice were infertile (data not shown).
17-DMAG preferentially degrades mutant AR protein and significantly increases Hsp70 and Hsp40 in SBMA mice
Treatment with 17-DMAG significantly diminished both the high-molecular-weight complex and the monomeric mutant AR in the spinal cord and muscle of AR-97Q mice (P , 0.05), but only slightly diminished the wild-type monomeric AR in AR-24Q mice ( Fig. 6A and B ). In the AR-97Q mice, monomeric AR decreased by 71% in the spinal cord and 70% in the skeletal muscle, but only by 37 and 27%, respectively, in the AR-24Q mice ( Fig. 6A and B) . RT-PCR in both AR-24Q and AR-97Q mice showed that the levels of AR mRNA were similar in the treated (Tg-10) and untreated (Tg-0) mice (Supplementary Material, Fig. S6 ), implying that the decreased protein was due to degradation and not to lower mRNA levels. We also conducted filter-trap assays (Supplementary Material) for both the large molecular weight aggregated and the soluble forms of mutant AR. Both forms of trapped AR-97Q protein were markedly reduced in the spinal cord and muscle of treated mice (Supplementary Material, Fig. S7 ). These observations indicate that 17-DMAG preferentially degrades not only the high-molecular-weight mutant AR complex but also the monomeric mutant AR protein.
17-DMAG treatment of transgenic mice was also accompanied by marked chaperone induction. The levels of Hsp70 and Hsp40 in the spinal cord were increased by 367 (P , 0.005) and 105% (P , 0.0001), respectively, and in the muscle by 235 (P , 0.05) and 195% (P , 0.0001), respectively ( Fig. 6C and D) following 17-DMAG treatment. These pharmacological effects of 17-DMAG on chaperone induction were more pronounced than those of 17-AAG in our previous study (11) . The enhanced chaperone induction accompanying 17-DMAG treatment might be responsible for its enhanced pharmacological effect of reducing mutant AR.
Immunohistochemical staining for mutant AR showed a significant reduction in 1C2-positve diffuse nuclear staining and NIs in the spinal anterior horn (Fig. 6E ) and skeletal muscle (Fig. 6F ) in the Tg-10 mice (Fig. 6G) . Anti-glial fibrillary acidic protein (GFAP) staining showed an apparent reduction in reactive astrogliosis in the Tg-10 mice in the spinal anterior horn (Fig. 6H) . Muscle histology also demonstrated marked amelioration of muscle atrophy in the Tg-10 mice (Fig. 6I) . AR-24Q mice and normal littermates treated with 17-DMAG displayed no altered phenotypes (data not shown).
DISCUSSION
The UPS is responsible for the turnover of most soluble proteins and plays an essential role in degrading short-lived regulatory proteins and damaged or misfolded proteins (37) . We demonstrated that UPS activity during the advanced stage of SBMA model mice, assessed by chymotryptic activity and ubiquitin-dependent protein-degradation activity, was very well preserved in the spinal cord and even increased in the skeletal muscle. More importantly, the expression levels of 20S proteasome a1 and a7 subunits appeared to be elevated in the 1C2-positive muscle fibers (Supplementary Material,  Fig. S4 ). In addition, UPS function semi-quantitatively evaluated in the GFP-based (Ub G76V -GFP) reporter mouse (31) was also not impaired, data that are concordant with a previous study of an ataxia model of polyQ disease (25) . Further evidence of preserved proteasomal function in the AR-97Q mice exhibiting advanced SBMA phenotypes is the data showing that protein levels of proteasome subunits in AR-97Q mice were similar to those in the AR-24Q mice in the spinal motor neurons and increased in skeletal muscle. Earlier studies of polyQ -mediated degeneration in cultured cell models (16, 18, 38) , transgenic mice (39) and human postmortem samples (40) showed that components of the UPS are sequestrated in cellular aggregates or NIs, suggesting involvement of the UPS in polyQ diseases. The function of the UPS was evaluated in various assays that provided divergent results, ranging from impaired (19 -21,24) to preserved (28,29) UPS function. It is possible that mutant polyQexpanded proteins may directly affect proteasome function within the specific subcellular compartment of synaptic UPS activities (23) , although it has been demonstrated that neuronal dysfunction can develop without significant impairment of the UPS in a mouse model of SCA7 (25) . Consistent with this is data showing that proteasome impairment did not contribute to the pathogenesis of Huntington's disease in a mouse model (26) . Furthermore, in conditional knockout mouse models of polyQ disease, genetic diminution of the abnormal gene led to rapid clearance of pre-existing polyQ aggregates and reversible improvement of abnormal phenotypes (41, 42) . If the UPS were irreversibly damaged in patients and animal models of polyQ diseases, then the aggregates of pathogenic proteins could not have been eliminated. Taking these data together, we considered that UPS function is well preserved in polyQ diseases, particularly in SBMA, and treatment with 17-DMAG, which enhances a self-clearing system of target disease-causing proteins via the UPS, is a reasonable therapeutic strategy against polyQ-related diseases. On the other hand, it is known that an age-dependent decrease in proteasome activity exists that may reduce the clearance of the misfolded proteins, resulting in their accumulation and contributing to late-onset polyQ-expanded toxicity. UPS-related genes were suppressed at the transcriptional level in the aged brain (43) , and proteasome activity was also decreased in the aged brain (27, 44) , although brain proteasome activity was not specifically altered in the brains of Huntington's disease knock-in mice when compared with age-matched wild-type mice (27) . As proteasome activity generally decreases in the central nervous system in aged animals (27, 44) , such an age-dependent decrease in UPS function is unlikely to critically contribute to the region-specific neuropathology seen in different types of polyQ diseases. We present a potent strategy for SBMA therapy, with 17-DMAG acting via a preserved or elevated proteasome activity. 17-DMAG has two major activities, preferential client protein degradation and Hsp induction; the present study revealed that polyQ-expanded mutant AR was preferentially degraded by treatment with 17-DMAG. Mutant AR elimination was mediated through its preferential incorporation into the Hsp90-chaperone complex (11, 45) , where it is prone to proteasomal degradation. Our present results in a transgenic mouse model also confirmed that 17-DMAG passes through the blood-brain barrier as previously reported (46) and that it demonstrates sufficient pharmacological effects in the central nervous system. We have already examined the effectiveness of 17-AAG in a mouse model of SBMA (11). 17-AAG has less toxicity (47) and higher selectivity (45) for client oncoproteins than does geldanamycin (48). 17-DMAG has a potential advantage over 17-AAG because its aqueous solubility eliminates the need for complicated formulations used to administer 17-AAG, and 17-DMAG induced the up-regulation of Hsp70 more than 17-AAG did (49) . In a mouse study, the bioavailability of 17-DMAG by oral administration was twice that of orally delivered 17-AAG (46). Data from preclinical toxicity studies for 17-DMAG in animal models have recently become available (50) and phase I clinical trials for cancer are currently being performed (51, 52) . In addition, 17-DMAG is not metabolized to the potentially toxic metabolites that arise from CYP3A-mediated metabolism of the 17-allyl side chain of 17-AAG (14, 46, 53) , indicating that 17-DMAG has less toxic side effects than 17-AAG. In fact, 17-DMAG shows greater oral bioavailability than 17-AAG, the pharmacological effect of 17-DMAG for mutant AR degradation was three times that of 17-AAG (Fig. 4C and D) , and the inductions of Hsp70 and Hsp40 with 17-DMAG were more pronounced than with 17-AAG in the SBMA mouse model (Fig. 6C and D) (11) . Moreover, the concentration necessary to obtain a similar therapeutic efficacy using 17-DMAG (10 mg/ kg) was much lower than that using 17-AAG (25 mg/kg) ( Fig. 5A-D) (11) . Although 17-DMAG passes through the blood-brain barrier less than 17-AAG in vivo (14, 46) , these data show that 17-DMAG has more potent effects than 17-AAG.
Hsp90 inhibitors also function as Hsp inducers (54, 55) , resulting in the dissociation of HSF-1 from the Hsp90 complex and subsequent HSF-1 trimerization, thereby leading to Hsp activation (11) . In this study, the inductions of Hsp70 and Hsp40 with 17-DMAG were more pronounced than with 17-AAG in our previous study (11) . Hsps, particularly Hsp70, were shown to suppress aggregate formation and cellular toxicity in polyQ disease models (9, 16, 56) . Hsp70 over-expression also enhanced degradation of polyQ-expanded proteins via its interaction with the UPS (36, 57) . CHIP (carboxyl terminus of Hsc70-interacting protein) might be one such coupling factor between the Hsp70 chaperone system and the machinery responsible for degrading mutant proteins (58, 59) . Thus, enhancement of chaperone expression using Hsp90 inhibitors under preserved UPS function is a further reasonable clinical approach for the treatment of pathogenic mutant or modified protein-mediated neurodegenerative diseases.
In conclusion, we have demonstrated that UPS function was well preserved or even enhanced in an SBMA model mouse and that 17-DMAG exerted potent therapeutic effects on the SBMA phenotype. In the case of other neurodegenerative diseases, phosphorylated tau would be one of the target proteins of Hsp90 inhibitors (60) . Hsp90 inhibitors have also been shown to be effective in animal models of Parkinson's disease (61) , stroke (62) and autoimmune encephalomyelitis (63) . The combined therapy of 17-DMAG and leuprorelin would be expected to be more effective than the monotherapy with either 17-DMAG or leuprorelin (64) , because the target sites of the agents are different and thus the therapeutic effect of the combined therapy would theoretically be additive or synergistic. 17-DMAG, by directly reducing diseasecausing protein, presents a new therapeutic avenue for SBMA and has potentially widespread applications for other neurodegenerative diseases, particularly if the disease-causing protein belongs to the Hsp90 client protein family.
MATERIALS AND METHODS
DNA transfection
Full-length AR cDNAs were constructed by subcloning AR inserts into the pCR3.1 mammalian expression vector (Invitrogen) (11) . SH-SY5Y cells were plated in 6 cm dishes in 5 ml of DMEM/F12 containing 10% fetal bovine serum with penicillin and streptomycin, and each dish was transfected with 8 mg of vector containing AR24, AR97 or mock (negative control) constructs using OPTI-MEM (Invitrogen) and Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. The cells were cultured for 48 h at 378C under 5% CO 2 . Transfection efficiency was 60-70% in both AR-24Q and AR-97Q transfected cells, and no difference in transfection efficiencies was found. In this culture system, we detected a band of monomeric mutant AR in the separating gel, but barely detected the high-molecular-weight mutant AR protein complex, which was retained in the stacking gel. Therefore, this cultured cell model is better suited for estimating changes in monomeric mutant AR expression. For transgenic mice, the dosing solutions of 17-DMAG in saline were freshly prepared weekly. 17-DMAG treatments were started when mice were 5 weeks old and were continued until they were 16 weeks (or 25 weeks for toxicity studies). An optimal dose of 17-DMAG was determined based on a previous study in mice (50) . Male AR-24Q and AR-97Q mice received 0.2 ml oral administration of 1 or 10 mg/kg 17-DMAG three times a week on alternate days; control mice received saline alone. Members of the same litter were distributed among the three treatment groups and homogeneities of body weight variances and means among the three groups were confirmed using Bartlett's test and one-way ANOVA.
Assay of proteasome activity
Mouse tissue homogenates from the spinal cord and muscle of 16-week-old AR-24Q and AR-97Q mice were clarified by centrifugation at 15 000 g and subjected to 8 -32% (v/v) linear glycerol density gradient centrifugation (22 h, 83 000g). Proteasome chymotrypsin-like peptidase activity was measured using the peptide substrate, succinyl-Leu-Leu-Val-Tyr-7-amino-4-methyl-coumarin in the absence (i.e. 26S proteasome) of 0.025% sodium dodecyl sulfate (SDS) as described previously (65) . For the assay of cIAP1 (inhibitor of apoptosis-1) degradation, cDNAs encoding Flag-cIAP1 subcloned into pcDNA3.1 were transcribed in vitro, translated and radiolabeled. The 35S-labeled Flag-cIAP1 was purified using M2-agarose (Sigma) and eluted with Flag-peptide (Sigma). The results were confirmed by duplicate measurements of the samples from different mice. For ubiquitination of cIAP1, 3 000 000 c.p.m. of 35S-labeled cIAP1, 0.25 mg of E1, 0.9 mg of UbcH5 and 33 mg of ubiquitin (Sigma) were mixed and incubated in a volume of 80 ml for 90 min at 308C, as described previously (66) . Finally, 2.5 ml of the ubiquitination mixture was added to 10 ml of cell lysate in the presence of 2 mM ATP, incubated at 378C for 20 min and then radioactivities of trichloroacetic acid-soluble fractions were measured.
Generation and maintenance of TG mice and genotyping
We crossed the mice expressing full-length human AR with 24-(AR-24Q mice, 5-5 line) or 97-polyQ tracts (AR-97Q mice, 7-8 line) with Ub G76V -GFP/1 line. The Ub
G76V
-GFP/1 line was obtained from Dr Nico P. Dantuma in the Department of Cell and Molecular Biology, Karolinska Institute, and maintained in the B6 background. We screened mouse-tail DNA by PCR for the presence of the transgene using the primer sets as described previously (30, 31) .
Neurological and behavioral assessment of SBMA model mice
The AR-24Q and AR-97Q mice were generated and maintained as previously described (67) . The AR-97Q male mice showed progressive muscular atrophy and weakness as well as diffuse nuclear staining and NIs consisting of mutant AR. These phenotypes were very pronounced in male transgenic mice similar to SBMA patients (30) . All animal experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and under the approval of the Nagoya University Animal Experiment Committee. The mouse Rotarod task was performed using an Economex Rotarod (Ugo Basile), and cage activity was measured with the AB system (BrainScience Idea Osaka, Japan) as described previously (30, 68) . The investigators in the behavioral assessment were blinded to the treatments.
Protein expression analysis
Cells were lysed in CelLytic-M Mammalian Cell Lysis/ Extraction Reagent (Sigma) with 1 mM PMSF and 6 mg/ml aprotinine and centrifuged at 15 000g for 15 min at 48C, 48 h after transfection. Sixteen-week-old mice were exsanguinated under ketamine -xylazine anesthesia 12 h after the final treatment of 17-DMAG, and tissues were snap-frozen with powdered CO 2 in acetone. The tissues were homogenized in CelLytic-M Mammalian Cell Lysis/Extraction Reagent (Sigma) with 1 mM PMSF and 6 mg/ml aprotinine and centrifuged at 2500g for 15 min at 48C. Supernatant fraction protein concentrations were determined using the DC protein assay (Bio-Rad). Aliquots of supernatant fractions were loaded on 5 -20% SDS -PAGE gels, each lane containing 7 mg protein for cells, 160 mg for nervous tissue and 80 mg for muscular tissue, and then transferred to Hybond-P membranes (GE Healthcare) using 25 mM Tris, 192 mM glycine, 0.1% SDS and 10% methanol as transfer buffer. Primary antibodies were used at the following concentrations: rabbit anti-AR (1:1000, H280; Santa Cruz or 1:1000, N-20; Santa Cruz); mouse anti-Hsp70 (1:1000, SPA-810; Assay Designs); rabbit anti-Hsp40 (1:5000, SPA-400; Assay Designs); mouse anti-Hsp90 (1:1000, F-8; Santa Cruz); mouse anti-Hop (1:1000, SRA-1500; Assay Designs); mouse anti-p23 (1:1000, MA3-414; Affinity BioReagents); rabbit anti-p85 (1:2000, Upstate); and mouse anti-a-tubulin (1:5000, T9026; Sigma); mouse anti-GFP (1:5000, MAB3580; Millipore); anti-20S proteasome subunits a3, a4, a5 and a6 (Biomol); anti-20S proteasome subunits b2, b3, b4, b5i, b6 and b7 (Biomol); anti-19S proteasome subunits Rpt1, Rpt2, Rpt3, Rpt4, Rpt5 and Rpt6 (Biomol); rabbit anti-11S proteasome regulator (PA28) PA28a, PA28b, PA28g subunits (Biomol); rabbit anti-20S proteasome a1, a2, a7, b1; mouse anti-19S proteasome subunit Rpn2; and rabbit anti-19S proteasome subunits Rpn1, Rpn7, Rpn8 (1:1000) (65, 69, 70) . Primary antibodies were probed using HRP-conjugated anti-rabbit Ig F (ab 0 ) 2 and anti-mouse Ig F (ab 0 ) 2 (1:5000, GE Healthcare) secondary antibodies and detected with the ECLþplus kit (GE Healthcare). An LAS-3000 imaging system was used to produce digital images and to quantify band intensities, which were then analyzed with Image Gauge software version 4.22 (Fujifilm, Tokyo, Japan). Densitometric values of AR, Hsp70, Hsp40 and GFP were normalized to those of endogenous p85 or a-tubulin. Relative signal intensity (RSI) was computed as the signal intensity of each sample divided by that of the Tg-0 mice (Fig. 6) or the 24Q/GFP mice (Fig. 2) .
Immunoprecipitation from cultured cells was performed using 300 mg total protein lysate from cells, 10 ml Protein G Sepharose (GE Healthcare) and 5 ml anti-AR antibody (N-20; Santa Cruz). For experiments involving co-precipitation of AR, cells were lysed in molybdate-containing lysis buffer (10 mM Tris pH 7.4, 10 mM monothioglycerol, 10 mM Na 2 MoO 4 , 10 mM MgCl 2 , 0.2% Tween-20, 1 mM PMSF and 6 mg/ml aprotinine). For the AR ubiquitination assay, a fulllength AR was constructed by subcloning AR inserts derived from pCR-AR97 (97 CAG repeats) into the pDsRed monomer mammalian expression vector (Takara Bio, Otsu, Japan) (59) . SH-SY5Y cells were seeded onto 60-mm plates and transfected with plasmids encoding DsRed-AR97 for a 48 h period. Cells were exposed to MG132 (20 mM) for a 1 h period and to MG132 (20 mM) and 17-DMAG (10 mM) for a 4 h period. Extracts were prepared and AR was immunoprecipitated with anti-DsRed antibody. Blots were probed with ubiquitin (1B3; MBL) and AR (N20; Santa Cruz) antibody.
Filter-trap assay
To quantify the large-molecular aggregated and soluble form of the mutant AR protein, filter-trap assays of total tissue homogenates from the spinal cord and muscle of male AR-24Q or AR-97Q mice (16 weeks old) were performed as previously described (36) . Filtration of proteins through a 0.2 mm cellulose acetate membrane (Sartorius AG) was performed using a slot-blot apparatus (Bio-Rad). Only the larger-sized mutant AR protein was retained on the cellulose acetate membrane (pore 0.2 mm in diameter), whereas the nitrocellulose membrane captured protein of all sizes. In each case, the nitrocellulose membrane was placed under the cellulose acetate membrane to capture the soluble AR protein passing through this membrane. The membranes, supported by two pieces of filter paper (Bio-Rad), were washed three times with TBS buffer. Samples of protein, 200 mg for the spinal cord and 80 mg for the muscle, were prepared in a final volume of 200 ml lysis buffer, loaded and gently vacuumed. Membranes were washed three times with TBS containing 0.05% Tween-20. Slot-blots were probed as described for western blots by an antibody against AR (H-280; Santa Cruz) or a-tubulin (T9026; Sigma).
Quantitative real-time RT -PCR
The levels of AR and proteasomal subunit mRNAs were determined by real-time RT -PCR as described previously (11) . Total RNA was isolated from SH-SY5Y cells using the RNeasy Mini Kit (QIAGEN) and from transgenic mouse spinal cord and muscle by homogenizing in Trizol (Invitrogen) according to the manufacturer's instructions. Total RNA (5 mg) from cells and mouse spinal cord and muscle were reverse transcribed using SuperScript III reverse transcriptase (Invitrogen). PCR primers were designed to amplify GFP cDNA sequences in GFP-reporter mouse tissues (5 0 -TATAT CATGGCCGACAAGCA and 5 0 -TGTTCTGCTGGTAGT GGTCG) (Fig. 2) , proteasomal subunit cDNA sequences in mouse tissues (Psm a3: QT00168728, Psm a5: QT00137928, Psm a6: QT00124439, Psm b1: QT00121079, Psm b5: QT 00111216, Psm c5: QT00162022 and Psm e3: QT00167797) (QIAGEN) (Supplementary Material, Fig. S3 ) and AR cDNA sequences in mouse tissues (5 0 -TTCCACACCCAGTGAAG C-3 and 5 0 -CCTGAGGAGTGAATTGATCC-3 0 ) (Supplementary Material, Fig. S5 ). Real-time RT -PCR was carried out in a total volume of 50 ml, containing 25 ml of 2Â QuantiTect SYBR Green PCR Master Mix (QIAGEN) and 10 mM of each primer. PCR products were detected by the iCycler system (Bio-Rad). The reaction conditions were 958C for 15 min and then 45 cycles of 15 s at 948C, 30 s at 558C and 30 s at 728C. As an internal standard control, the expression level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was simultaneously quantified using the primers (5 0 -CTCAGAGGAG CCCAGATGA-3 0 and 5 0 -GCTGGTCTTGCGGTACAGT-3 0 ) for mouse tissues. RSI was computed as the signal intensity of each sample divided by that of the AR-24Q/GFP mice (Fig. 2) , the AR-24Q mice (Supplementary Material, Fig. S3 ) or the Tg-0 mice (Supplementary Material, Fig. S5 ).
RNA interference
Oligonucleotide siRNA duplexes were synthesized by Takara Bio. siRNA sequences were as follows: scramble (control) siRNA, 5 0 -CAAUACUGAAGUAUCAACG-3 0 ; Hsp70 siRNA, 5 0 -CGAAAGACAACAAUCUGUU-3 0 . Transfection was done using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Hsp70 was efficiently downregulated upon siRNA exposure (Fig. 4H) .
Cell viability assay
MTS-based cell proliferation assays were performed in triplicate using the CellTiter 96 w AQueous One Solution Cell Proliferation Assay (Promega) 48 h after incubation with 17-DMAG.
Immunohistochemistry and histopathology
Mice were deeply anesthetized with ketamine -xylazine and transcardially perfused with 20 ml of 4% paraformaldehyde fixative in phosphate buffer (pH 7.4). Tissues were post-fixed overnight in 10% phosphate-buffered formalin and processed for paraffin embedding. At room temperature, 6 mm thick tissue sections were deparaffinized, dehydrated with alcohol and treated with formic acid for 5 min. The tissue sections were blocked with normal horse serum (1:20) and incubated with mouse anti-expanded polyQ antibody (1:10 000, 1C2; Millipore); mouse anti-GFAP antibody (1:1000, Boehringer Manheim Biochemica, Manheim, Germany); anti-20S proteasome subunits a4, a5, b2; anti-19S proteasome subunit Rpt3 (Biomol); and rabbit anti-20S proteasome a1 and a7. Primary antibodies were probed with a biotinylated anti-species specific IgG secondary antibodies (Vector Laboratories) and the immune complexes visualized using streptavidin-horseradish peroxidase (Dako) and 3,3 0 -diaminobenzidine as a substrate. Sections were counterstained with Mayer's hematoxylin. Paraffin-embedded, 6 mm thick sections of the gastrocnemius muscles were air-dried and stained with hematoxylin and eosin. Tissues from the GFP-reporter mice were post-fixed in 4% PFA in PBS (pH 7.4) for 16 h at 48C. The tissues were immersed in a graded series of sucrose solutions in 0.01 M PBS at 48C as follows: 3 h in 7% sucrose, 3 h in 14% sucrose and 16 h in 25% sucrose. The tissues were then embedded in Tissue-Tek OCT compound (Sakura Finetek) and frozen with powdered solid CO 2 in acetone (71) . Because native GFP fluorescence was below the detection threshold in both the spinal cord and skeletal muscle, the expression of Ub G76V -GFP was evaluated semi-quantitatively by immunohistochemistry with an anti-GFP antibody. Cryostat sections, 10 mm thick, were prepared from the frozen tissues and blocked with 5% goat serum, incubated with rabbit anti-GFP antibody (1:1000, NB600-308; Novus Biologicals) at 48C overnight, and then incubated with Alexa 488-conjugated goat anti-rabbit IgG (1:1000; Invitrogen) at 48C overnight. The stained sections were examined and photographed with a confocal laser scanning microscope (LSM 5 PASCAL; Carl Zeiss). To assess GFP-reporter expression levels in spinal anterior horn cells, immunohistochemistry signal intensities were quantified in at least 10 transverse sections from each mouse. Images of individual anterior horn cells on transverse sections of the spinal cord with signals for Ub G76V -GFP reporter were captured at the desired magnification and stored with image software (Olympus, Tokyo, Japan). Levels of reporter in the images were quantitatively analyzed with image analysis software (WinROOF version 5, Mitani, Fukui, Japan). Signal intensities were expressed as individual intracellular signal levels of Ub G76V -GFP reporter (arbitrary absorbance units) in spinal anterior horn cells by subtracting the mean background levels of three regions of interest in each section. For doubleimmunofluorescence staining of the spinal cord and skeletal muscle, sections were blocked with 5% normal goat serum and then sequentially incubated with anti-20S proteasome a1 or a7 subunit (1:200) and 1C2 antibody (1:10 000) at 48C overnight. The sections were then incubated with Alexa 488-conjugated goat anti-rabbit IgG (1:1000; Molecular Probes) and Alexa 568-conjugated goat anti-mouse IgG (1:1000; Molecular Probes) for 8 h at 48C. The stained sections were examined and photographed with a confocal laser scanning microscope (LSM 5 PASCAL; Carl Zeiss MicroImaging, Tokyo, Japan).
In situ hybridization
Formalin-fixed, paraffin-embedded 6 mm thick sections of spinal cord and skeletal muscle were processed for in situ hybridization using the Ventana Discovery system (Ventana) according to the manufacturer's instructions. GFP cDNA was obtained using the primers 5 0 -CCTGAAGTTCATCTGC ACCA-3 0 and 5 0 -GTTCACCTTGATGCCGTTCT-3 0 . Digoxigenin-labeled cRNA antisense and sense probes of 350 bp were generated for in situ hybridization from linearized plasmids for Ub G76V -GFP reporter using Sp6 and T7 polymerases (Roche), respectively. No hybridization signal was observed with the sense probe for the expression of Ub G76V -GFP reporter (data not shown). To assess gene expression levels in spinal anterior horn cells, signal intensities of in situ hybridization were quantified in at least 10 transverse sections from each mouse. Images of individual anterior horn cells on transverse sections of the spinal cord with signals for Ub G76V -GFP reporter were captured at the desired magnification and stored with image software (Olympus). Signal levels of the images were quantitatively analyzed with image analysis software (WinRoof version 5) and expressed as individual intracellular cytoplasmic signal levels (arbitrary absorbance units) of spinal anterior horn cells for Ub G76V -GFP reporter by subtracting the mean background levels of three regions of interest in each section.
Quantification of 1C2-positive cells, glial cell reaction and muscle fiber size For assessment of 1C2-positive cells, 6 mm thick coronal sections of the thoracic spinal cord and gastrocnemius muscle stained with 1C2 antibody (1:10 000, Millipore) were prepared and the number of 1C2-positive cells in each individual mouse was counted using a light microscope with a computerassisted image analyzer (Luzex FS, Nikon, Tokyo, Japan). For assessment of 1C2-positive cells in the ventral horn of the spinal cord, 50 consecutive transverse sections of the thoracic spinal cord were prepared and 1C2-positive cells within the ventral horn of every fifth section were counted as described previously (64) . Populations of 1C2-positive cells were expressed as the number per mm 2 . For assessment of 1C2-positive cells in muscle, the number of 1C2-positive cells was calculated from counts of more than 500 fibers in randomly selected areas and expressed as the number per 100 muscle fibers. The quantitative data of six individual mice were expressed as mean+SE.
Hematological examination
AST and ALT were measured by ultraviolet spectrophotometry, BUN by the Urease-GLDH UV assay and Cre by an enzyme assay (Mitsubishi Kagaku Bio-Clinical Laboratories, Tokyo, Japan).
Statistical analyses
Data were analyzed by unpaired t-tests in Figures 1B, 2 , 4B, 4D, 5F and 6 and Supplementary Material, Figures S1, S3, S5 and S6 and Kaplan -Meier and log-rank tests for survival rate in Figure 5D using Statview software version 5 (HULINKS, Tokyo, Japan). Statistical significance of the drug -dose dependency of phenotypes in Figure 5A -C was examined by the Williams test for multiple comparisons using Microsoft Excel 2004 (Microsoft).
